Home
Faculty Directory
Jeffrey E. Pessin, Ph.D.

Jeffrey E. Pessin, Ph.D.

Professor, Department of Medicine (Endocrinology)

Professor, Department of Molecular Pharmacology

Judy R. and Alfred A. Rosenberg Professorial Chair in Diabetes Research

Director, Department of Medicine Diabetes Research Center

Area of Research: Regulation of glucose metabolism Epigenetic modifications regulating metabolism Regulation of lipogenic gene transcription and de novo lipogenesis Cardiometabolic health adipocyte and liver biology Integrative metabolic signaling

Contact Information

718.678.1029jeffrey.pessin@einsteinmed.edu

Albert Einstein College of Medicine
Michael F. Price Center
1301 Morris Park Avenue, Room 375
Bronx, NY 10461

Research Profiles Einstein Media Expert

More Resources: Diabetes Research and Training Center

Is this your profile? Edit profile

Professional Interests

The Pessin laboratory is analyzing insulin signaling at the molecular level, the regulation of glucose uptake and metabolism at the cellular, molecular level and the integrative systems of metabolism in normal and pathophysiologic states in genetic rodent models. Our efforts have been focused on three major aspects of insulin signaling and insulin sensitivity. These areas include the molecular mechanisms of adipose tissue inflammation leading to fibrosis and programmed cell death, the regulation of insulin/nutriebt signaling in the regulation of liver gluconeogenesis and lipogenesis and there dysregulation in states of insulin resistance.

One major laboratory project is the investigation of adipocyte progenitor cells, adipocyte programmed cell death and adipose tissue fibrosis that is induced by high fat feeding. In these studies, we have utilized a variety of experimental approaches including genetically engineered mice, Fluorescent Activated Cell Sorting (FACS) analyses and sorting along RNA-Seq and single nuclei RNA-Seq. In these analyses we isolated a variety of inflammatory specific cell types within adipose tissue and have taken extensive use of RNAseq technology to characterize the expression profiles of these various cell subsets. This approach has allowed us to develop a functional understanding of the signaling interplay between the adipose tissue immune cell types to determine the specific role each cell is playing in the inflammatory response. In collaboration with the laboratory of Kosaku Shinoda we are exploring the relationship between metabolism, autophagy and energy balance in adipocyte lineage determination (brown, beige and white) as a potential therapeutic approach for both diabetes and obesity.

A second major laboratory project is based upon our recent findings in collaboration with the laboratory of Fajun Yang that in the fed state CDK8/CycC complex directly phosphorylates the nuclear form of SREBP-1c that induces an E3 ligase mediated ubiquitination and proteasome-mediated degradation of SREBP-1c. This process is one of several that is required to maintain nuclear SREBP1-c at very low levels thereby suppresses lipogenic gene expression and lipogenesis. However, n the fed state, CDK8/CycC proteins are rapidly down regulated through a mTORC1 dependent pathway leading to increased SREBP-1c stability and increased lipogenic gene expression and lipogenesis. During the past two years, we have developed a robust research team, several key mouse genetic models, human liver biopsy speciments and cell based approaches to investigate the regulation of liver gluconeogenesis abd lipogenesis in normal and pathophysiologic states of insulin resistance, obesity and non-alcoholic fatty liver disease (NFALD). In these approaches we perform various high-through put DNA sequencing technologies (ie: RNA-seq, single cell RNA-seq, ChIP-seq, 3 dimensional DNA conformation capture (Hi-C) that are used to directly assess the epigenetic basis of normal and pathological liver metabolic funciton.

We have also initiated new studies to examine the development of heart failure in diabetic cardiomyopathy. New data from the laboratory indicates that increasing glycolytic rate in cardiomyocytes markedly protects the heart from myocardial infarction. In collaboration with the laboratory of Gaetano Santulli, we are examining the mechanistic basis for this novel observation as a means to specifcally prevent heart damage and failure that progressively occurs following myocardial infarction.

Selected Publications

The Mediator complex kinase module is necessary for fructose regulation of liver glycogen levels through induction of glucose-6-phosphatase catalytic subunit (G6pc).

Youn DY, Xiaoli AM, Zong H, Okada J, Liu L, Pessin J, Pessin JE, Yang F.Mol Metab. 2021 Jun;48:101227. doi: 10.1016/j.molmet.2021.101227. Epub 2021 Mar 31.PMID: 33812059

Conversion of the death inhibitor ARC to a killer activates pancreatic β cell death in diabetes.

McKimpson WM, Chen Y, Irving JA, Zheng M, Weinberger J, Tan WLW, Tiang Z, Jagger AM, Chua SC Jr, Pessin JE, Foo RS, Lomas DA, Kitsis RN.Dev Cell. 2021 Mar 22;56(6):747-760.e6. doi: 10.1016/j.devcel.2021.02.011. Epub 2021 Mar 4.PMID: 33667344

ATG16L1 autophagy pathway regulates BAX protein levels and programmed cell death.

Chen F, Amgalan D, Kitsis RN, Pessin JE, Feng D.J Biol Chem. 2020 Oct 30;295(44):15045-15053. doi: 10.1074/jbc.RA120.013999. Epub 2020 Aug 26.PMID: 32848017

The Impact of Single-Cell Genomics on Adipose Tissue Research.

Deutsch A, Feng D, Pessin JE, Shinoda K.Int J Mol Sci. 2020 Jul 5;21(13):4773. doi: 10.3390/ijms21134773.PMID: 32635651

FAM83G Is a Novel Inducer of Apoptosis.

Okada J, Sunaga N, Yamada E, Saito T, Ozawa A, Nakajima Y, Okada K, Pessin JE, Okada S, Yamada M.Molecules. 2020 Jun 18;25(12):2810. doi: 10.3390/molecules25122810.PMID: 32570757

Regulation of gene expression during the fasting-feeding cycle of the liver displays mouse strain specificity.

Chi Y, Youn DY, Xiaoli AM, Liu L, Pessin JB, Yang F, Pessin JE.J Biol Chem. 2020 Apr 10;295(15):4809-4821. doi: 10.1074/jbc.RA119.012349. Epub 2020 Feb 19.PMID: 32075912

SNAP23 depletion enables more SNAP25/calcium channel excitosome formation to increase insulin exocytosis in type 2 diabetes.

Liang T, Qin T, Kang F, Kang Y, Xie L, Zhu D, Dolai S, Greitzer-Antes D, Baker RK, Feng D, Tuduri E, Ostenson CG, Kieffer TJ, Banks K, Pessin JE, Gaisano HY.JCI Insight. 2020 Feb 13;5(3):e129694. doi: 10.1172/jci.insight.129694.PMID: 32051343

Dapagliflozin Inhibits Cell Adhesion to Collagen I and IV and Increases Ectodomain Proteolytic Cleavage of DDR1 by Increasing ADAM10 Activity.

Okada J, Yamada E, Saito T, Yokoo H, Osaki A, Shimoda Y, Ozawa A, Nakajima Y, Pessin JE, Okada S, Yamada M.Molecules. 2020 Jan 23;25(3):495. doi: 10.3390/molecules25030495.PMID: 31979355

Quick Links

Faculty Profile

Jeffrey E. Pessin, Ph.D.

Contact Information

Professional Interests

Selected Publications

Related News

Feature

A New Generation of Scientists Takes on Liver Disease

Research Brief

Gaining Insights into Brown Fat

News Release

NIH Awards $9.5 Million for Einstein-Mount Sinai Diabetes Research Center

News Release

NIH Grants $10.5 Million for Einstein-Mount Sinai Diabetes Research Center

About Einstein

Administration

Alumni

Careers

Centers (Research)

Contact Us

Departments

Diversity

Donors

Education

Einstein Senate

Faculty Directory

Health

INTRANET

Library

Luminis Portal

Newsroom

Policies

Research

Video

Visitors

Webmail